Dishman Carbogen

What does Dishman Carbogen do?

Dishman Carbogen Amcis Ltd provides Contract Research and Manufacturing Services in the Pharmaceuticals & Biotechnology sector. As of March 2025, it reported net sales of ₹716 Cr and a net profit of ₹43 Cr, with a market cap of ₹4,226 Cr.

Overview:<BR>Dishman Carbogen Amcis Ltd is engaged in Contract Research and Manufacturing Services (CRAMS) within the Pharmaceuticals & Biotechnology industry and is categorized as a Small Cap company.<BR><BR>History:<BR>The company was incorporated as Carbogen Amcis (India) Limited in 2007 and later changed its name to Dishman Carbogen Amcis Limited on March 27, 2017. The latest quarterly results reported net sales and profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 716 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 43 Cr (Quarterly Results - Mar 2025)<BR>- Market Cap: Rs 4,226 Cr (Small Cap)<BR><BR>Key Metrics:<BR>- P/E: 191.00<BR>- Industry P/E: 35<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: 0.32<BR>- Return on Equity: 0.38%<BR>- Price to Book: 0.73<BR><BR>Contact Details:<BR>Address: Dishman Corporate House, Iscon-Bopal Road Ambli Ahmedabad Gujarat : 380058<BR>Tel: 91-2717-400102/124<BR>Email: grievance@dishmangroup.com<BR>Website: htts://imdcal.com

Has Dishman Carbogen declared dividend?

Dishman Carbogen Amcis Ltd has declared a 10% dividend, amounting to ₹0.2 per share, with an ex-date of September 12, 2019. However, there have been no dividends declared since then, resulting in a 0% dividend return across multiple periods despite significant price returns.

Dishman Carbogen Amcis Ltd has declared a 10% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 10%<BR>- Amount per share: 0.2<BR>- Ex-date: 12 Sep 19<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -0.48%, the dividend return was 0%, resulting in a total return of -0.48%.<BR><BR>Over the past year, the price return was 85.25%, with a dividend return of 0%, leading to a total return of 85.25%.<BR><BR>In the last 2 years, the price return was 116.96%, while the dividend return remained at 0%, culminating in a total return of 116.96%.<BR><BR>For the 3-year period, the price return was 124.29%, with a dividend return of 0%, resulting in a total return of 124.29%.<BR><BR>In the 4-year period, the price return was 27.47%, and the dividend return was 0%, leading to a total return of 27.47%.<BR><BR>Over the last 5 years, the price return was 273.97%, with a dividend return of 0%, resulting in a total return of 273.97%.<BR><BR>Overall, Dishman Carbogen has declared a dividend in the past, but there have been no dividends declared since then, as indicated by the 0% dividend return across multiple periods. The company has shown significant price returns over the years, particularly in the 5-year period, despite the absence of recent dividends.

Who are the peers of the Dishman Carbogen?

Dishman Carbogen's peers include Aarti Drugs, Sequent Science, Hikal, Unichem Labs, RPG LifeScience, Gujarat Themis Bio, Orchid Pharma, Gufic BioScience, and Advanced Enzyme. RPG LifeScience shows excellent management risk and the highest 1-year return at 44.57%, while Orchid Pharma has the lowest return at -34.27%.

Peers: The peers of Dishman Carbogen are Aarti Drugs, Sequent Scien., Hikal, Unichem Labs., RPG LifeScience., Guj. Themis Bio., Orchid Pharma, Gufic BioScience, and Advanced Enzyme.<BR><BR>Quality Snapshot: Excellent management risk is observed at RPG LifeScience, while Good management risk is found at Aarti Drugs, Hikal, Guj. Themis Bio., Gufic BioScience, and Advanced Enzyme, and the rest have Average or Below Average management risk. Growth is Below Average for Aarti Drugs, Sequent Scien., Hikal, RPG LifeScience, Guj. Themis Bio., Orchid Pharma, and Advanced Enzyme, while Average growth is seen at Unichem Labs. and Gufic BioScience, and the rest have Below Average growth. Capital Structure is Excellent for RPG LifeScience, Guj. Themis Bio., Gufic BioScience, and Advanced Enzyme, Good for Aarti Drugs and Unichem Labs., Average for Hikal, and Below Average for Sequent Scien., Dishman Carbogen, Orchid Pharma, and Zota Health Care.<BR><BR>Return Snapshot: RPG LifeScience has the highest 1-year return at 44.57%, while Orchid Pharma has the lowest at -34.27%, with Dishman Carbogen's own 1-year return at 57.24% being significantly higher than both. Additionally, Orchid Pharma and Advanced Enzyme have negative six-month returns.

Who are in the management team of Dishman Carbogen?

As of March 2022, the management team of Dishman Carbogen includes Janmejay R Vyas (Chairman), Deohooti J Vyas (Whole-time Director), Arpit J Vyas (Managing Director & CFO), and several independent directors, along with a Company Secretary. This team oversees the company's operations and governance.

As of March 2022, the management team of Dishman Carbogen includes the following individuals:<BR><BR>1. Janmejay R Vyas - Chairman (Non-Executive)<BR>2. Deohooti J Vyas - Whole-time Director<BR>3. Arpit J Vyas - Managing Director & CFO<BR>4. Sanjay S Majmudar - Independent Director<BR>5. Ashok C Gandhi - Independent Director<BR>6. Subir Kumar Das - Independent Director<BR>7. Rajendra S Shah - Independent Director<BR>8. Shrima Dave - Company Secretary & Compliance Officer<BR>9. Maitri K Mehta - Independent Director<BR><BR>This team comprises a mix of executive and independent directors, along with a compliance officer, overseeing the company's operations and governance.

Who are the top shareholders of the Dishman Carbogen?

The top shareholders of Dishman Carbogen include Adimans Technologies LLP with 59.32%, individual investors with 25.31%, and Mukul Mahavir Agrawal holding 5.5%. Additionally, foreign institutional investors hold 9.49%, and mutual funds have a combined stake of 1.06%, with no pledged promoter holdings reported.

The top shareholders of Dishman Carbogen include the promoters, with Adimans Technologies LLP holding the highest stake at 59.32%. Additionally, individual investors collectively own 25.31% of the company. Among public shareholders, Mukul Mahavir Agrawal is notable with a holding of 5.5%. The company also has 61 foreign institutional investors (FIIs) holding 9.49% and 6 mutual fund schemes with a combined holding of 1.06%. There are no pledged promoter holdings reported.

How big is Dishman Carbogen?

As of 24th July, Dishman Carbogen Amcis Ltd has a market capitalization of 4,061.00 Cr, with net sales of 2,711.50 Cr and a net profit of 3.24 Cr for the latest four quarters. The balance sheet as of March 2024 shows shareholder's funds of 5,627.50 Cr and total assets of 9,570.62 Cr.

As of 24th July, Dishman Carbogen Amcis Ltd has a market capitalization of 4,061.00 Cr, categorizing it as a Small Cap company.<BR><BR>For the latest four quarters, the company reported net sales of 2,711.50 Cr and a net profit of 3.24 Cr.<BR><BR>As of March 2024, the balance sheet shows shareholder's funds amounting to 5,627.50 Cr and total assets of 9,570.62 Cr.

When is the next results date for Dishman Carbogen?

Dishman Carbogen is scheduled to declare its results on 04 November 2025.

Dishman Carbogen is scheduled to declare its results on 04 November 2025.

Is Dishman Carbogen overvalued or undervalued?

As of November 6, 2025, Dishman Carbogen is considered fairly valued with a PE ratio of 28.07, an EV to EBITDA of 10.39, and a Price to Book Value of 0.72, outperforming the Sensex with a 37.05% return over the past year.

As of 6 November 2025, Dishman Carbogen's valuation grade has moved from very attractive to attractive, indicating a shift in market perception. The company is currently considered fairly valued. Key ratios include a PE ratio of 28.07, an EV to EBITDA of 10.39, and a Price to Book Value of 0.72. <BR><BR>In comparison to its peers, Dishman Carbogen's PE ratio is lower than that of Sun Pharma, which stands at 35.02, and significantly lower than Divi's Lab at 79.09. However, it is on par with Cipla, which has a PE of 22.27, and Dr. Reddy's Labs at 17.42. Notably, Dishman Carbogen has outperformed the Sensex over the past year with a return of 37.05% compared to the Sensex's 3.65%, reinforcing its current valuation status.

How has been the historical performance of Dishman Carbogen?

Dishman Carbogen's historical performance shows steady growth in net sales from INR 2,140.69 crore in March 2022 to INR 2,711.50 crore in March 2025, with improved profitability indicators, including a profit after tax of INR 3.24 crore in March 2025. Total liabilities and assets increased, reflecting a stronger financial position, while cash flow from operations remained stable.

Answer:<BR>The historical performance of Dishman Carbogen shows a fluctuating trend in key financial metrics over the years leading up to March 2025.<BR><BR>Breakdown:<BR>Dishman Carbogen's net sales have shown a steady increase from INR 2,140.69 crore in March 2022 to INR 2,711.50 crore in March 2025. The total operating income followed a similar trend, rising from INR 2,140.69 crore in March 2022 to INR 2,711.50 crore in March 2025. However, the total expenditure, excluding depreciation, increased from INR 1,809.32 crore in March 2022 to INR 2,242.56 crore in March 2025, impacting the operating profit, which saw a rise to INR 468.94 crore in March 2025 from INR 331.37 crore in March 2022. Despite this, the profit before tax turned positive at INR 19.31 crore in March 2025 after being negative in the previous years. The profit after tax also improved to INR 3.24 crore in March 2025 from a loss of INR 153.45 crore in March 2024. On the balance sheet, total liabilities increased to INR 9,986.34 crore in March 2025 from INR 8,634.20 crore in March 2022, while total assets rose to INR 9,986.34 crore in March 2025, indicating a growth in the company's financial position. Cash flow from operating activities remained relatively stable, with INR 375 crore in March 2025, while net cash inflow was recorded at INR 76 crore for the same period. Overall, Dishman Carbogen has shown signs of recovery and growth in its financial performance over the past few years.

Is Dishman Carbogen technically bullish or bearish?

As of December 2, 2025, the market trend for Dishman Carbogen has shifted to mildly bearish, indicated by bearish MACD readings and Bollinger Bands on the weekly chart, despite some short-term support from daily moving averages.

As of 2 December 2025, the technical trend has changed from sideways to mildly bearish. The current stance is mildly bearish, supported by the weekly and monthly MACD readings, both indicating a bearish momentum. The Bollinger Bands show a bearish signal on the weekly chart, while the daily moving averages are mildly bullish, suggesting some short-term support. The KST and OBV are also mildly bearish on the weekly timeframe. Overall, the combination of these indicators points to a bearish sentiment in the current market environment for Dishman Carbogen.

Are Dishman Carbogen Amcis Ltd latest results good or bad?

The latest results for Dishman Carbogen Amcis Ltd are concerning, as the company achieved record sales of ₹719.80 crores but reported a net loss of ₹12.97 crores, indicating significant operational challenges and a negative profit margin. Overall, these results are considered bad, raising concerns about the company's profitability and operational efficiency.

The latest results for Dishman Carbogen Amcis Ltd are concerning. While the company reported its highest quarterly sales ever at ₹719.80 crores, it simultaneously recorded a significant net loss of ₹12.97 crores. This represents a dramatic decline in profitability, with a negative profit after tax (PAT) margin of -1.80%, marking the worst quarterly performance in terms of profitability in recent history.<BR><BR>The operating margin also saw a sharp contraction, decreasing by 710 basis points to 15.71%. This indicates substantial operational challenges and cost pressures that the company is facing. Despite the increase in sales, the inability to convert this revenue into profit raises serious questions about operational efficiency and margin sustainability.<BR><BR>Overall, the results reflect a troubling disconnect between revenue growth and profitability, leading to heightened concerns among investors about the company's operational health and future prospects. Given these factors, the latest results can be characterized as bad, highlighting significant issues that need to be addressed for any potential recovery.

Should I buy, sell or hold Dishman Carbogen Amcis Ltd?

Why is Dishman Carbogen Amcis Ltd falling/rising?

As of 30-Apr, Dishman Carbogen Amcis Ltd's stock is currently at Rs 183.60, reflecting a 1.27% increase, with a strong performance over the past week and month. Despite a decline in investor participation, the stock's attractive valuation and significant profit growth suggest potential for future growth.

As of 30-Apr, Dishman Carbogen Amcis Ltd's stock price is rising, currently at Rs 183.60, reflecting a change of 2.3 (1.27%) upward. The stock has shown a strong performance over the past week, with a return of +5.15%, significantly outperforming the Sensex, which declined by -0.97%. Additionally, the stock has experienced a remarkable increase of +41.23% over the past month, while the Sensex only rose by +6.90%.<BR><BR>Today's trading session has also been positive, with the stock reaching an intraday high of Rs 185.6, marking a 2.37% increase. Despite a day's low of Rs 174.35, the overall performance today has outperformed the sector by 0.77%. However, it is important to note that there has been a decline in investor participation, with delivery volume falling by -51.63% compared to the 5-day average.<BR><BR>From a valuation perspective, the company has a very attractive ROCE of 3.2 and is trading at a discount compared to its peers' average historical valuations. Although the stock has generated a return of -4.75% over the past year, its profits have surged by 233.1%, resulting in a low PEG ratio of 0.1, which suggests potential for future growth.<BR><BR>In summary, the stock's rise can be attributed to strong short-term performance, attractive valuation metrics, and significant profit growth, despite some concerns regarding long-term fundamentals and declining investor participation.

Which are the latest news on Dishman Carbogen?